Healthcare provider profile · identity verified

Brittany J Devries, AGNP

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · GRAND RAPIDS, MI · NPI 1104429851

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Brittany J Devries, AGNP received $9.77 in general payments during 2025 across 1 reported records.

Boston Scientific Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$9.77

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Boston Scientific Corporation Unresolved — no canonical attribution shown $9.77100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$9.771

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Bulkamid
Normalized: bulkamid
Device Boston Scientific Corporation $9.77 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Tramadol HclTramadol Hcl18623
GabapentinGabapentin17936
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17925
Sertraline HclSertraline Hcl14635
FurosemideFurosemide13735
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13618
LorazepamLorazepam13426
EliquisApixaban12318
Levothyroxine SodiumLevothyroxine Sodium10724
LisinoprilLisinopril10520
FamotidineFamotidine8818
Metoprolol SuccinateMetoprolol Succinate8817
XareltoRivaroxaban86suppressed
Potassium ChloridePotassium Chloride8322
Atorvastatin CalciumAtorvastatin Calcium7728
AlprazolamAlprazolam68suppressed
MirtazapineMirtazapine6814
Amlodipine BesylateAmlodipine Besylate6515
Trazodone HclTrazodone Hcl6217
Duloxetine HclDuloxetine Hcl6111
ClonazepamClonazepam60suppressed
PregabalinPregabalin59suppressed
Quetiapine FumarateQuetiapine Fumarate5719
JardianceEmpagliflozin55suppressed
Citalopram HbrCitalopram Hydrobromide5418
Morphine SulfateMorphine Sulfate5118
OmeprazoleOmeprazole5114
Metformin HclMetformin Hcl4915
Escitalopram OxalateEscitalopram Oxalate4713
LacosamideLacosamide47suppressed
Divalproex SodiumDivalproex Sodium44suppressed
SpironolactoneSpironolactone44suppressed
Ropinirole HclRopinirole Hcl42suppressed
AripiprazoleAripiprazole40suppressed
RisperidoneRisperidone39suppressed
JanuviaSitagliptin Phosphate38suppressed
LevetiracetamLevetiracetam38suppressed
Methadone HclMethadone Hcl38suppressed
Pantoprazole SodiumPantoprazole Sodium38suppressed
BumetanideBumetanide36suppressed
Buspirone HclBuspirone Hcl36suppressed
Ondansetron HclOndansetron Hcl3514
Warfarin SodiumWarfarin Sodium33suppressed
ArexvyRsvpref3 Antigen/As01e/Pf3232
Losartan PotassiumLosartan Potassium3213
Dicyclomine HclDicyclomine Hcl31suppressed
Memantine HclMemantine Hcl31suppressed
AllopurinolAllopurinol29suppressed
Humalog Kwikpen U-100Insulin Lispro29suppressed
Midodrine HclMidodrine Hcl29suppressed
Morphine Sulfate ErMorphine Sulfate29suppressed
DiazepamDiazepam26suppressed
OlanzapineOlanzapine26suppressed
ClopidogrelClopidogrel Bisulfate24suppressed
Donepezil HclDonepezil Hcl23suppressed
Propranolol HclPropranolol Hcl23suppressed
ClozapineClozapine21suppressed
FentanylFentanyl21suppressed
LamotrigineLamotrigine20suppressed
LatanoprostLatanoprost20suppressed
Metformin Hcl ErMetformin Hcl19suppressed
NystatinNystatin19suppressed
Trifluoperazine HclTrifluoperazine Hcl18suppressed
Breo ElliptaFluticasone/Vilanterol17suppressed
Fluticasone PropionateFluticasone Propionate17suppressed
TradjentaLinagliptin17suppressed
Venlafaxine Hcl ErVenlafaxine Hcl17suppressed
CephalexinCephalexin1614
Insulin Glargine-YfgnInsulin Glargine-Yfgn1611
MetolazoneMetolazone16suppressed
TrulicityDulaglutide16suppressed
CarvedilolCarvedilol15suppressed
FinasterideFinasteride15suppressed
Ciprofloxacin HclCiprofloxacin Hcl14suppressed
DigoxinDigoxin14suppressed
Fluoxetine HclFluoxetine Hcl14suppressed
Tamsulosin HclTamsulosin Hcl14suppressed
Albuterol Sulfate HfaAlbuterol Sulfate13suppressed
Diclofenac SodiumDiclofenac Sodium13suppressed
ImiquimodImiquimod13suppressed
Methenamine HippurateMethenamine Hippurate13suppressed
MethotrexateMethotrexate Sodium13suppressed
TopiramateTopiramate13suppressed
Verapamil HclVerapamil Hcl13suppressed
Diltiazem 24hr ErDiltiazem Hcl12suppressed
Insulin Aspart FlexpenInsulin Aspart12suppressed
Kapspargo SprinkleMetoprolol Succinate12suppressed
Oxybutynin ChlorideOxybutynin Chloride12suppressed
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11suppressed
Insulin LisproInsulin Lispro11suppressed
PrednisonePrednisone11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $9.77 · 1 records Boston Scientific Corporation Bulkamid
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error